Alembic Pharmaceuticals Limited announced that its wholly-owned subsidiary Alembic Global Holding SA has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) treprostinil injection, 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), multiple-dose vials.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Remodulin injection, 20 mg/20 mL (1mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10mg/mL), of United Therapeutics Corp.Treprostinil injection is indicated for the treatment of pulmonary arterial to diminish symptoms associated with exercise.In patients with PAH requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. Alembic had previously received tentative approval for this ANDA.Treprostinil injection has an estimated market size of US$ 17 million for twelve months ending December 2020, according to IQVIA.Alembic now has a total of 138 ANDA approvals (121 final approvals and 17 tentative approvals) from US FDA, including this first injectable ANDA approval.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!